The Interplay of Growth Hormones and Aging - Episode 363

Dr. Gladden and Dr. Matt Kaeberlein dives into the complexities of aging, discussing its biological underpinnings, the role of growth hormones and mTOR, and the potential of rapamycin in extending healthspan. They also explore the Dog Aging Project, highlighting insights from canine studies, and the profound connection between humans and their pets. The conversation concludes with a discussion on GLP-1 and SGLT-2 medications and their implications for aging and chronic disease management. In this conversation, Dr. Gladden and Matt Kaeberlein delve into the latest advancements in aging research, discussing the potential of GLP-1 agonists and SGLT2 inhibitors, the role of hormones in aging, and the impact of AI on medical research. They explore the regulatory challenges faced by longevity medicine, the opportunities and risks associated with gene therapy, and the central mechanisms of aging and reprogramming. The discussion highlights the complexities of aging biology and the potential for innovative interventions to enhance healthspan and lifespan.

For Audience

Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!

Takeaways

· Definitions matter in understanding aging.

· Aging is an exponential biological process, not linear.

· mTOR is a volume knob, not an on-off switch.

· Rapamycin shows promise with minimal side effects.

· Balance between growth and recycling is crucial.

· Social environments for dogs lower disease risk.

· Oxytocin plays a significant role in health.

· Clinical trials can yield misleading results.

· SGLT2 inhibitors may slow aging in animal models.

· Companion animals can help reduce chronic stress. GLP-1 agonists and SGLT2 inhibitors show promise in modulating aging biology.

· Hormones play a crucial role in aging and longevity.

· AI technology is rapidly advancing and could revolutionize aging research.

· Regulatory bodies like the FDA may slow down innovation in longevity medicine.

· Gene therapy presents both opportunities and risks in the field of aging.

· Epigenetic reprogramming has the potential for significant positive effects on healthspan.

· Not all aspects of aging can be reversed through current interventions.

· The understanding of aging biology is still evolving and requires more research.

· There are central mechanisms of aging that could be targeted for rejuvenation.

· The future of aging research is likely to involve a combination of therapies and technologies.

Chapters

00:00 Understanding Aging: A Biological Perspective

02:47 The Role of Growth Hormones and mTOR in Aging

06:08 Rapamycin: Potential Benefits and Considerations

09:04 The Dog Aging Project: Insights from Canine Studies

17:02 The Connection Between Humans and Dogs

26:52 Exploring GLP-1 and SGLT-2 Medications

28:12 Exploring GLP-1 Agonists and SGLT2 Inhibitors

30:19 The Role of Hormones in Aging

34:55 AI's Impact on Aging Research

39:41 Regulatory Challenges in Longevity Medicine

42:02 Gene Therapy: Opportunities and Risks

46:40 Central Mechanisms of Aging and Reprogramming To learn more about Dr. Matt Kaeberlein:IG: instagram.com/mkaeberlein LinkedIn: https://www.linkedin.com/in/mkaeberlein/

Reach out to us at:

Website: https://gladdenlongevity.com/ Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw